中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

53 records (took 0.028 seconds)

    Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
    11.
    发明授权
    Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity 有权

    公开(公告)号：US12279989B2

    公开(公告)日：2025-04-22

    申请号：US17738771

    申请日：2022-05-06

    Applicant: Seed Health Inc.

    Inventor： Joseph E. Kovarik

    IPC: A61F5/56

    Abstract: A method and system for increasing beneficial bacteria populations in a subject's oral cavity and decreasing pathogenic bacteria to address a variety of diseases and conditions, thereby enhancing a person's oral and overall health, including through the use of oral strips that adhere to surfaces in the oral cavity and that include at least one of xylitol, Lachnospira, Veillonella, Faecalibacterium and/or Rothia bacteria, including bacteria transformed via a CRISPR system. Certain embodiments employ light to modify oral cavity bacterial populations, including the use of bioluminescent oral strips that promote the growth of beneficial bacteria and decrease pathogenic bacteria populations.

    Probiotic Method and Composition for Maintaining a Healthy Vaginal Microbiome
    15.
    发明公开
    Probiotic Method and Composition for Maintaining a Healthy Vaginal Microbiome 审中-公开

    公开(公告)号：US20230390343A1

    公开(公告)日：2023-12-07

    申请号：US18232433

    申请日：2023-08-10

    Applicant: Seed Health, Inc.

    Inventor： Sheri Simmons ,  Tye Jensen ,  Joseph E. Kovarik

    IPC: A61K35/74 ,  A61K31/58 ,  A61K31/715 ,  A61K38/17

    CPC classification number: A61K35/74 ,  A61K31/58 ,  A61K31/715 ,  A61K38/1709 ,  A61K38/1758 ,  A61K2035/11

    Abstract: A method to reduce the likelihood of a dysbiosis of the vaginal microbiome in an individual employing a probiotic method and composition for maintaining a healthy vaginal microbiome, with particular embodiments including a bacterial formulation of at least two live bacteria selected from the group consisting of L. reuteri, L johnsonii and L. crispatus, and at least one prebiotic having glycogen as a component thereof. The bacterial formulation is administered to an individual's vagina in an amount sufficient for the bacterial formulation to generate an amount of tryptophan metabolites sufficient to act as aryl hydrocarbon receptor (AHR) agonists, thereby reducing inflammation in the individual's vagina. Certain embodiments include increasing the production of SCFAs in the individual's gut microbiome, while reducing the production of SCFAs in the individual's vagina and introducing ammonia oxidizing microorganisms to the individual's vagina.

    Topical Application of CRISPR-Modified Bacteria to Treat Acne Valgaris
    17.
    发明公开
    Topical Application of CRISPR-Modified Bacteria to Treat Acne Valgaris 审中-公开

    公开(公告)号：US20230218682A1

    公开(公告)日：2023-07-13

    申请号：US18178847

    申请日：2023-03-28

    Applicant: Seed Health, Inc.

    Inventor： Tye JENSEN ,  Joseph E. KOVARIK

    IPC: A61K35/74 ,  A61K31/58 ,  A61K31/715 ,  A61K38/17 ,  A61K35/00

    CPC classification number: A61K35/74 ,  A61K31/58 ,  A61K31/715 ,  A61K38/1758 ,  A61K38/1709 ,  A61K2035/11

    Abstract: Compositions, systems and methods of improving the health of the microbiome of an individual's skin relate to the provision of skin contacting formulations containing beneficial bacteria and other microbe components to foster the growth and maintenance of a healthy skin microbiome. Embodiments include methods for treating an individual suffering from acne valgaris by topically administering a composition that includes live bacteria selected from the group consisting of L reuteri, L johnsonii, L crispatus, C. acnes, and Nitrosomonas eutropha, that have been modified by using a using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1 (Cpf1) system to reduce the production of a virulence factor of the bacteria.

    Method and System to Reduce the Likelihood of Dental Caries and Halitosis
    18.
    发明公开
    Method and System to Reduce the Likelihood of Dental Caries and Halitosis 审中-公开

    公开(公告)号：US20230165706A1

    公开(公告)日：2023-06-01

    申请号：US18103768

    申请日：2023-01-31

    Applicant: SEED HEALTH .INC.

    Inventor： Tye Jensen ,  Joseph E Kovarik

    IPC: A61F5/56

    CPC classification number: A61F5/566

    Abstract: A method to facilitate the growth of desired bacteria in a human's mouth to reduce the likelihood of dental caries and halitosis and other oral diseases, and for inhibiting oral biofilm formation, gingivitis, periodontitis and halitosis via the employment of one or more probiotic bacterial, bioactive flavonoid, and zinc compound compositions effective in providing prevention and treatment options.

    Method for Treating Individuals Having Cancer and who are Receiving Cancer Immunotherapy
    19.
    发明申请
    Method for Treating Individuals Having Cancer and who are Receiving Cancer Immunotherapy 有权

    公开(公告)号：US20220378853A1

    公开(公告)日：2022-12-01

    申请号：US17854422

    申请日：2022-06-30

    Applicant: SEED HEALTH, INC.

    Inventor： Joseph E. Kovarik

    IPC: A61K35/74 ,  A61K31/715 ,  A61K31/58 ,  A61K38/17

    Abstract: The methods described herein are for treating infections in individuals having cancer and who are receiving cancer immunotherapy, preferably employing a CRISPR system to selectively kill or reduce the numbers of pathogenic bacteria within the individual and thereafter, administering an immune checkpoint inhibitor thereto. In particular embodiments, the pathogenic bacteria is one of E. coli, Pseudomonas aeruginosa, Klebsiella bacteria, Staphylococcus aureus; Streptoccocus; Salmonella; Shigella; Mycobacterium tuberculosis; Enterococcus; Clostridium; Neisseria gonnorrhoea; Acinetobacter baumannii; and Campylobacter bacteria and the checkpoint inhibitor is selected from the group consisting of nivolumab, pembrolizumab, pidilizumab, AMP-224, AMP-514, STI-A1110, TSR-042, RG-7446, BMS-936559, MEDI-4736, MSB-0020718C, AUR-012 and STI-A1010. Further embodiments include enhancing the growth of a second bacteria in the individual, such bacteria including Akkermansia, Bacteroides, Bifidobacterium, Enterococcus, Fusobacterium, Coprococcus, LactoBacillus, Propionibacterium, Ruminococcus, Veillonella, Prevotella, and F. prausnitzii. The CRISPR system may include Cas9, Cpf1 and Cas3, and may be delivered using a bacteriophage.

    Method and System for Reducing the Likelihood of Developing Colorectal Cancer in an Individual Human Being
    20.
    发明申请
    Method and System for Reducing the Likelihood of Developing Colorectal Cancer in an Individual Human Being 有权

    公开(公告)号：US20220296655A1

    公开(公告)日：2022-09-22

    申请号：US17835204

    申请日：2022-06-08

    Applicant: SEED HEALTH, INC.

    Inventor： Joseph E. Kovarik

    IPC: A61K35/74 ,  A61K31/715 ,  A61K31/58 ,  A61K38/17

    Abstract: A method for reducing the likelihood of an individual developing colorectal cancer includes the use of a CRISPR system to selectively kill pathogenic bacteria, such as Klebsiella and E. coli, within the individual. Preferrably, the growth of a beneficial bacteria, such as Akkermansia, Bacteroides, Bifidobacterium, Clostridium, Enterococcus, Fusobacterium, Coprococcus, Lactobacillus, Propionibacterium, Ruminococcus, Veillonella, Prevotella, and Streptococcus bacteria, is also enhanced. Reduction of certain virulence factors, such as colibactin, using a CRISPR system, as well the employment of immune checkpoint inhibitors, is effective in treating individuals with cancer and who suffer from a chronic infectious disease.

Patent Agency Ranking